Taken together, the multitude of available CD38-targeting agents that exhibit efficacy in myeloma and other CD38+ malignancies need to be studied extensively in the solid tumor field in order to identify which tools will provide the best anti-tumor response in solid tumors. The gene discussed is CD38; the disease is neoplasm.